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Background: In sub-Saharan Africa, malaria is the leading cause of morbidity and mortality especially in children.
In Senegal, seasonal malaria chemoprevention (SMC) previously referred to as intermittent preventive treatment in
children (IPTc) is a new strategy for malaria control in areas of high seasonal transmission. An effectiveness study of
SMC, using sulphadoxine-pyrimethamine (SP) plus amodiaquine (AQ), was conducted in central Senegal from 2008
to 2010 to obtain information about safety, feasibility of delivery, and cost effectiveness of SMC. Here are report the
effect of SMC delivery on the prevalence of markers of resistance to SP and AQ.
Methods: This study was conducted in three health districts in Senegal with 54 health posts with a gradual
introduction of SMC. Three administrations of the combination AQ + SP were made during the months of
September, October and November of each year in children aged less than 10 years living in the area. Children
were surveyed in December of each year and samples (filter paper and thick films) were made in 2008, 2009 and
2010. The prevalence of mutations in the pfdhfr, pfdhps, pfmdr1 and pfcrt genes was investigated by sequencing
and RTPCR in samples positive by microscopy for Plasmodium falciparum.
Results: Mutations at codon 540 of pfdhps and codon 164 of pfdhfr were not detected in the study. Among
children with parasitaemia at the end of the transmission seasons, the CVIET haplotypes of pfcrt and the 86Y
polymorphism of pfmdr1 were more common among those that had received SMC, but the number of infections
detected was very low and confidence intervals were wide. The overall prevalence of these mutations was lower in
SMC areas than in control areas, reflecting the lower prevalence of parasitaemia in areas where SMC was delivered.
Conclusion: The sensitivity of P. falciparum to SMC drugs should be regularly monitored in areas deploying this
intervention. Overall the prevalence of genotypes associated with resistance to either SP or AQ was lower in SMC
areas due to the reduced number of parasitaemia individuals.
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In many parts of sub-Saharan Africa, malaria remains the
leading cause of morbidity and mortality in children.
Malaria caused an estimated 216 million cases of clinical
malaria and 655 thousand deaths in 2010 [1]. In areas of
seasonal malaria transmission, the burden of severe
disease and mortality due to malaria is mainly among
children under five years of age. Seasonal malaria chemo-
prevention (SMC) previously referred to as intermittent
preventive treatment in children (IPTc), is a new control
strategy suited to areas of high seasonal transmission.
SMC is defined as the intermittent administration of full
treatment of an anti-malarial medicine during the mal-
aria season to prevent malarial illness with the objective
of maintaining therapeutic anti-malarial drug concen-
trations in the blood throughout the period of greatest
malarial risk [2].The World Health Organization now
recommends that children living in areas of high seasonal
transmission should receive treatment with sulphadoxine-
pyrimethamine (SP) plus amodiaquine (AQ) each month
for up to four months during the peak transmission
period. SP and AQ currently retain their efficacy in areas
where SMC is recommended but it is important that sen-
sitivity of parasites to SMC drugs is monitored in areas
where it is introduced.
The presence of Plasmodium falciparum dihydrofolate
reductase (pfdhfr) triple mutation (codon 108, 51 and 59)
together with double P. falciparum dihydropteorate syn-
thetase (pfdhps) mutations at codons 437 and 540 is
associated with resistance to SP [3,4]. In West Africa, the
mutation at codon 540 of the pfdhps is very rare and its
presence is a useful single marker of quintuple mutation
(triple pfdhfr plus double pfdhps). In addition to markers
of resistance to SP, mutations at P. falciparum chloro-
quine transporter (pfcrt) and P. falciparum multidrug
resistance (pfmdr1) genes should be assessed to monitor
SP+AQ efficacy in areas where SMC is implemented.
The pfcrt mutant haplotype (CVIET) based on codon
72–76, which mediates high levels of resistance to chloro-
quine (CQ), has been linked with moderate resistance to
AQ in Africa in the presence of particular haplotypes of
pfmdr1 [5,6]. IPTi in infants in Senegal with SP revealed
that despite an increase in the prevalence of individual
mutations, there was no major impact on dihydrofolate re-
ductase (pfdhfr) and dihydropteroate synthetase (pfdhps)
combined mutations [7].
In this study, the prevalence of molecular markers of
pfcrt and pfmdr1 was determined to evaluate the effec-
tiveness of the use of AQ, as in several studies in Mali
[8,9]. The aim of this study was to assess the preva-
lence of molecular markers of resistance to SP (pfdhfr
and pfdhps) and AQ (pfcrt and pfmdr1) in an area
where SMC using both drugs was being implemented
at large scale.Methods
Study site and subjects
According to the 2002 national census, approximately
450,000 people live in this area. The northern part of the
study area is part of the district medical Bambey while
the southern part of the district medical Fatick. There
are approximately 725 villages in the study area and 54
health posts run by health workers and two health cen-
ters directed by a medical doctor.
The study site and the implementation of SMC are de-
scribed by Cisse et al. [10]. In brief, SMC with SP+AQ
was administered once per month from September to
November to children in three districts in central Senegal
(Mbour, Bambey and Fatick) from 2008 to 2010. Imple-
mentation of SMC was phased in the 54 health posts.
Nine health posts delivered SMC in 2008, 27 health posts
in 2009, and 45 in 2010. Initially children aged three to
59 months were included in the programme; in 2009 the
upper age limit was increased to include all children less
than 10 years of age.
At the end of each transmission season, a cross-
sectional survey of children was conducted to measure
the prevalence of parasitaemia and to take blood sam-
ples on filter paper for analysis of molecular markers of
resistance to SMC drugs. In 2008, the population in the
catchment of 27 health posts was surveyed, including
the nine health posts that delivered SMC, and 18 control
health posts that did not deliver SMC. In 2009 and 2010,
all 54 health posts were included in the survey. Sampling
was stratified by health post area, with probably sam-
pling of individuals within each stratum.
For each child signed consent was obtained from a par-
ent or guardian after explaining the aims and procedures
of the survey. Filter paper samples from individuals who
had a positive blood film for P. falciparum were used to
determine the presence of mutations in genes pfdhfr,
pfdhps, pfmdr1 and pfcrt associated with resistance to SP
and to AQ by sequencing and Real Time PCR, to meas-
ure the impact of SMC on the prevalence of these muta-
tions at the end of each transmission season.
Ethical approval
The study was approved by the Ethics Committees of
the Ministry of Health, Senegal and the London School
of Hygiene & Tropical Medicine.
Laboratory methods
Microscopy
Thick smears were stored at room temperature for 48
hours, washed with pierval water, pH 7.2 and stained in
a 6% Giemsa solution for 20 minutes. Microscopy was
used to detect absence or presence of asexual and sexual
parasites. Total number of parasites seen and total num-
ber of white blood cells (WBCs) counted were used to
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8,000 WBCs. Quality control was performed by reading
10% of all slides by a different experienced laboratory
technician; in case of discrepancies a third reading was
performed and the average results obtained with the
two closest.
DNA extraction
The genomic DNA of the parasite was extracted from
filter papers reported positive after microscopic examin-
ation using the chelex method according to methods de-
scribed by Plowe et al. [11] and K76T was determined in
at least two multiplex real-time PCR runs using the
Rotorgene 3000 platform previously described [12]. 3D7,
Dd2 and 7G8 DNA obtained from the Malaria Research
Reagent Resource (MR4) were used to provide sequence-
specific positive control.
Genotyping
The genotype of the pfcrt gene for polymorphisms C72S
and K76T was determined in at least two multiplex real-
time PCR runs using the Rotorgene 3000 platform previ-
ously described [8]. 3D7, Dd2 and 7G8 DNA obtained
from the Malaria Research Reagent Resource (MR4)
were used to provide sequence-specific positive control.
Amplification of pfdhfr, pfdhps and pfmdr1 genes in-
volved primers is described in Table 1. All amplicons of
the pfdhfr, pfdhps and pfmdr1 genes were re-amplified on
a nested PCR step. Amplicons from nested PCR reaction
were purified using the QIA quick PCR Purification Kit
according to manufacturer’s instructions and subjected
to di-deoxy fluorescent sequencing (Big Dye 3.1) using
conditions and sequencing primers pairs. The sequence
of amplified DNA products was determined using ABI
PRISM Genetic Analyser. Chromas software was used to
analyse the sequence results. The DNA sequence was
compared with reference sequence of the pfdhfr, pfdhps
and pfmdr1 portions of the P. falciparum 3D7 clone
using Blast similar alignment. Primers sequences are
summarized in Table 1.
Statistical methods
For each mutation, are estimated the proportion, p1, of
genotyped samples that were positive for the mutation,
and its standard error, taking account of the different
survey design used in each year using the survey com-
mands in Stata 12 (StataCorp, College Station, Texas).
The prevalence of parasitaemia p2 are also estimated,
and its standard error. The prevalence of the different
mutations in the population were then estimated, based
on the prevalence of the mutation among genotyped
samples, and the overall prevalence of parasitaemia, i.e.
as p = p1 x p2, the standard error for log(p) obtained by
the delta method was used to calculate 95% confidenceinterval. Comparisons between intervention and control
areas were made by calculating the prevalence ratio,
again using the delta method for calculating standard er-
rors. Due to secular changes in prevalence of mutations
in the study area over time the year of sampling could
act as a confounder of the association between SMC and
the prevalence of mutations. Consequently, when com-
paring prevalence of mutations over the entire study
period (shown in Table 5), are accounted for the fact
that more health posts implemented SMC later in the
study (9/54 in 2008, 27/54 in 2009, 45/54 in 2010). By
adjusting for study year in the binomial regression
model used to estimate the prevalence ratios.
Results
Of the 2,721 children surveyed in 2008, blood samples
were obtained from 2,705 children. 84 were positive for
P. falciparum after microscopic examination of slides,
18/1,019 (1.8%) in the SMC area and 66/1,686 (3.9%) in
the control area (survey-adjusted prevalence ratio 0.30
(95% CI: 0.15, 0.61), p=0.001). In 2009, 6809 children
were surveyed, samples were obtained from 6,646, of
which 50 had positive blood films, 9/3,326 (0.27%) and
41/3320 (1.2%) respectively in the SMC and control
areas; aPR 0.16 (0.06, 0.42), p<0.001. In 2010, 1,098 were
surveyed, samples were obtained for 1,098 children, of
which 27 were positive by microscopy, 21/882 (2.4%)
and 6/216 (2.8%) respectively in the SMC and control
areas, aPR 0.71 (0.23, 2.20), p=0.55.
Pfdhfr polymorphisms
In 2008, 45 of 84 samples, all samples (43 and 27) in
2009 and 2010 were positive for P. falciparum by PCR.
The prevalence of IRNI triple-mutant haplotypes of
pfdhfr in 2008 stood at 7/8 (87.5%) in SMC villages ver-
sus 27/37 (72.9%) in control villages (survey-adjusted
p-value = 0.002). In 2009, the prevalence was 4/6 (66.6%)
in intervention villages and 27/34 (79.4%) in control vil-
lages (p = 0.50). In 2010, the prevalence of IRNI triple-
mutant was 19/21 (90.4%) and 4/4 (100%) in SMC villages
and control villages respectively (p = 0.46). The allele
I164L mutation was not found among Senegalese isolates
(Tables 2, 3, 4).
Pfdhps polymorphisms
All the 2008, 2009 and 2010 samples were wild-type for
the 540 codon of pfdhps. The prevalence of mutation of
pfdhps 437G allele was 7/8 (87.5%) in SMC villages ver-
sus 25/37 (67.56%) in control villages during the first
year (p = 0.50). After two and three years of implemen-
tation, prevalence was 4/6 (66.6%) and 18/21 (85.7%) in
SMC villages and 25/35 (71.4) and 4/4 (100%) in control
villages, respectively (p = 0.88 and p = 0.48 respectively).
The pfdhfr/pfdhps IRNI/GK quadruple mutant was 6/8







PCR1 dhfr_M1 5′-TTTATGATGGAACAAGTCTGC-3′ 650 93°C for 5min/(94°C for 30s- 54°C for 60s- 65°C for 60s) ×
41cycles/ 65° for 5min/ 15°C for 5min
Nested dhfr_M7 5′-CTAGTATATACATCGCTAACA-3′
dhfr-M9 5′-CTGGAAAAAATACATCACATTCATATG-3′ 594 95°C for 5min/(93°C for 30s- 56°C for 30s- 68°C for 75s) ×
30 cycles/ 75°C for 5min
Sequencing dhfr-M3 5′-TGATGGAACAAGTCTGCGACGTT-3′
dhfr-M9 5′-CTGGAAAAAATACATCACATTCATATG-3′ 96°C for 1min/(96°C for 30s- 50°C for 30s- 60°C for 4min) ×
26 cycles/4°C hold until ready to purify
dhfr-M3 5′-TGATGGAACAAGTCTGCGACGTT-3′
Pfdhps
PCR1 dhps-N1 5′-GATTCTTTTTCAGATGGAGG-3′ 770 94°C for 3min/(94°C for 30s- 55°C for 30s- 65°C for 60s) ×
30cycles / 65°C for 5min/ 15°C for 5min.
dhps-N2 5′-TTCCTCATGTAATTCATCTGA-3′ 711
Nested dhps-R2 5′-AACCTAAACGTGCTGTTCAA-3′ 94°C for 5min/(94°C for 30s- 60°C for 30s- 65°C for 1min) ×
30cycles /65°C for 5min/15°C for 5min.
dhps-R/ 5′-AATTGTGTGATTTGTCCACAA-3′
dhps-R2 5′-AACCTAAACGTGCTGTTCAA-3′ 96°C for 1min/(96°C for 30s-50°C-60°C for 4min) ×
26 cycles/ 4°C hold until ready to purify.
Sequencing dhps-R/ 5′-AATTGTGTGATTTGTCCACAA-3′
Pfmdr1
PCR1 fn1/1 5′-ACAAAAAGAGTACCGCTGAAT-3′ 578 94°C for 3min/(94°C for 30s- 55°C for 30s- 65°C for 1min) ×
30cycles/ 65°C for 5min/ 15°C for 5min.
rev/c1 5′-AAACGCAAGTAATACATAAAGTC-3′ 534
Nested mdr2/1 5′-ACAAAAAGAGTACCGCTGAAT-3′ 94°C for 3min/(94°C for 30s- 60°C for 30s- 65°C for 1min) ×
30cycles/ 65°C for 5min/ 15°C for 5min.
newrev1 5′-AAACGCAAGTAATACATAAAGTC-3′
Sequencing mdrfr1f-seq 5′-GTCGAATTATTTAGAAAAAT-3′ 96°C for 1min/(96°C for 30s- 50°C −60°C for 4min) ×
26cycles/4°C hold until ready to purify.
mdrfr1r-seq 5′-GCAAGTAATACATAAAGT-3′
Pfcrt
Crtd1 5′-TGTGCTCATGTGTTTAAACTT 5′- 166 94°C for 3min/(94°C for 30s- 55°C for 30s- 65°C for 1min) ×
30 cycles/ 65°C for 5min/15°C for 5min.
Crtd2 CAAAACTATAGTTACCAATTTTG
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and 23/37 (62.1), 23/34 (67.6%) and 4/4 (100%) in
control villages in 2008, 2009 and 2010, respectively (all
p-values > 0.2).
Pfcrt polymorphisms
The pfcrt haplotypes CVIET and CVMNK were success-
fully identified in 38 samples in 2008, 41 samples in
2009 and 27 samples in 2010. Prevalence of CVIET hap-
lotypes in intervention villages was 2/3 (66.6%) in 2008,
versus 8/35 (22.8%) in control villages (p = 0.038). It was
3/6 (50%) and 13/35 (37.1%), respectively, in SMC vil-
lages and control villages in 2009 (p=0.55). In 2010 the
CVIET haplotypes was found in 8/22 (36.3%) of positivesamples in SMC villages versus 2/5 (40%) in control vil-
lages (p=0.72) (Tables 2, 3, 4).
Pfmdr1 polymorphisms
Twenty-four samples from 2008, 40 samples from 2009
and 27 isolates from 2010 were successfully genotyped
for pfmdr1 at codon 86 and 184. In 2008, prevalence of
the mutation pfmdr1-86Y allele was 1/5 (20%) in SMC
villages, with no mutation was found at codon 86 in
control villages (p=0.066). In 2009, the prevalence was
4/6 (66.6%) in SMC villages and 15/33 (45.4%) in control
villages (p=0.03). In 2010, the 86Y mutation was ob-
served in 12/22 (54.5%) and no mutation in control vil-
lages (p=0.051). During the first year, mutant 184F
Table 2 Prevalence of resistance mutations in 2008 among those typed and estimated prevalence in the population
Study samples Prevalence in population$
Control area SMC area Control area SMC area Prevalence ratio^ p-value
SMC/ non SMC (95% CI)
Prevalence of parasitaemia: 66/1686 18/1019 4.86 1.46 0.30 (0.15, 0.61) 0.001
Prevalence of mutations
dhfr triple (51, 59, 108) 27/37 7/8 2.88 1.55 0.54 (0.25, 1.17) 0.12
dhps-437 25/37 7/8 2.68 1.55 0.58 (0.25, 1.34) 0.20
SP resistant mutant
(dhfr triple + dhps 437)
23/37 6/8 2.47 1.32 0.54 (0.22, 1.30) 0.17
crt CVIET mutation 8/35 2/3 0.87 1.18 1.36 (0.39, 4.71) 0.63
mdr 86Y 0/19 1/5 0 0.35 - -
mdr 184F 13/19 4/5 2.74 1.41 0.52 (0.23, 1.14) 0.10
AQ resistant mutant
(mdr 86Y + crt CVIET)
0/13 1/2 0 0.88 - -
SP resistant & AQ resistant 0/11 1/2 0 0.88 - -
^ Prevalence ratios accounting for survey design. $For genotypes, prevalence among population is estimated as the product of 1) the probability of a resistant
genotype among the typed samples and 2) the probability positive among samples with a definitive result (positive or negative) for asexual stage parasitaemia.
Standard errors estimated by the delta method as described in the methods section.
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control villages, respectively (p=0.33). In 2009, preva-
lence of this mutation was 5/6 (83.3) and 28/34 in SMC
and control villages (p=0.74). In 2010, this was 15/22
(68.1) and 2/5 in 2010, (p=0.56) (Tables 2, 3, 4).
Discussion
Malaria remains a major concern in Senegal, despite the
significant reduction in disease incidence observed in
parts of the country in recent years (according to data of
the National Malaria Control Programme of Senegal). ItTable 3 Prevalence of resistance mutations in 2009 among th
Study samples Pr





Prevalence of mutations among typed
dhfr triple (51, 59, 108) 27/34 4/6 0.9
dhps-437 25/35 4/6 0.8
SP resistant mutant
(dhfr triple + dhps 437)
23/34 4/6 0.8
crt CVIET mutation 13/35 3/6 0.4
mdr 86Y 15/33 4/6 0.5
mdr 184F 28/34 5/6 1.0
AQ resistant mutant
(mdr 86Y + crt CVIET)
9/33 2/6 0.3
SP resistant & AQ resistant 8/32 2/6 0.3
^ Prevalence ratios accounting for survey design. $For genotypes, prevalence amon
genotype among the typed samples and 2) the probability positive among samples
Standard errors estimated by the delta method as described in the methods sectiohas become urgent to find a new strategy for the preven-
tion of malaria especially among children less than ten
years residing in areas of seasonal malaria, for which
the risk of dying from malaria remains high. SMC with
SP+AQ is now recommended by WHO for the control
of malaria in areas of the Sahel and sub-Sahel with high
seasonal malaria transmission. However, the long-term
sustainability of SMC will depend on sensitivity of para-
sites to the anti-malarial drugs used. In this study, the
impact of the use of SP+AQ over the course of three







SMC/ non SMC (95% CI)
3 0.22 0.16 (0.06, 0.42) <0.001
8 0.18 0.18 (0.059, 0.58) 0.004
8 0.18 0.21 (0.064, 0.66) 0.008
4 0.18 0.22 (0.068, 0.69) 0.01
6 0.14 0.30 (0.10, 0.86) 0.026
6 0.18 0.32 (0.11, 0.92) 0.034
2 0.23 0.22 (0.086, 0.58) 0.002
4 0.09 0.27 (0.078, 0.92) 0.036
1 0.09 0.29 (0.08, 1.07) 0.064
g population is estimated as the product of 1) the probability of a resistant
with a definitive result (positive or negative) for asexual stage parasitaemia.
n.
Table 4 Prevalence of resistance mutations in 2010 among those typed and estimated prevalence in the population
Study samples Prevalence in population$
Control area SMC area Control area SMC area Prevalence ratio^ p-value
SMC/ non SMC (95% CI)
Prevalence of parasitaemia: 6/216 21/882 2.47 1.76 0.71 (0.23, 2.20) 0.55
Prevalence of mutations
dhfr triple (51, 59, 108) 4/4 19/21 2.78 2.15 0.78 (0.30, 1.98) 0.60
dhps-437 4/4 18/21 2.78 2.04 0.74 (0.28, 1.90) 0.52
SP resistant mutant
(dhfr triple + dhps 437)
4/4 18/21 2.78 2.04 0.74 (0.28, 1.90) 0.52
crt CVIET mutation 2/5 8/22 1.11 0.87 0.78 (0.15, 4.09) 0.77
mdr 86Y 0/5 12/22 0 1.30 - -
mdr 184F 2/5 15/22 1.11 1.62 1.46 (0.27, 8.05) 0.66
AQ resistant mutant
(mdr 86Y + crt CVIET)
0/5 5/22 0 0.54 - -
SP resistant & AQ resistant 0/4 5/21 0 0.57 - -
^ Prevalence ratios accounting for survey design. $For genotypes, prevalence among population is estimated as the product of 1) the probability of a resistant
genotype among the typed samples and 2) the probability positive among samples with a definitive result (positive or negative) for asexual stage parasitaemia.
Standard errors estimated by the delta method as described in the methods section.
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characterizing the prevalence of mutation in pfdhfr and
pfdhps genes, associated with resistance to SP, and genes
pfmdr1 and pfcrt, markers of resistance to CQ and AQ.
Among children with parasitaemia at the end of the
transmission season, the prevalence of mutation pfmdr1-
86Y was higher among children that had received SMC.
There was no strong evidence that the prevalence of
other mutations, among infected children, was different
in SMC and control areas. However, despite the large
sample size of these surveys, the number of positives
was low and confidence intervals were wide due to re-
duced transmission during the study period.
In each year, the overall prevalence of SP-resistant geno-
types was lower in SMC areas, as a consequence of the
marked reduction in prevalence of infection in areas using
SMC. For pfcrt-CVIET in 2008 and pfmdr1-184F in 2010,Table 5 Prevalence of resistance mutations among children w
Mutation Non-SMC area n
positive / N typed (%)
SMC area n positive /
N typed (%)
dhfr triple (51, 59, 108) 59/76 (77.6) 29/34 (85.3)
dhps-437 55/77 (71.4) 28/34 (82.4)
SP resistant mutant
(dhfr triple + dhps 437)
51/76 (67.1) 27/34 (79.4)
crt CVIET mutation 23/76 (30.3) 12/30 (40.0)
mdr 86Y 15/58 (25.9) 16/32 (50.0)
mdr 184F 44/59 (74.6) 23/32 (71.9)
AQ resistant mutant
(mdr 86Y + crt CVIET)
9/52 (17.3) 7/29 (24.1)
SP-AQ resistant 8/48 (16.7) 7/28 (25.0)
Prevalence ratios from binomial regression model with robust standard errors *Adjupoint estimates of the prevalence ratio were above 1, but
in both cases the confidence in intervals were wide.
Differences in the absolute prevalence of resistance ge-
notypes are seen most clearly in 2009, the year when
there were an equal number of clusters in the interven-
tion and control groups.
The presence of mutations at codons 540 of the pfdhps
gene and 164 of the pfdhfr gene was not detected in this
study. These mutations are considered as confirmed mar-
kers of resistance to SP, and appear associated with treat-
ment failure in East Africa [13]. The high prevalence of the
pfdhfr triple mutation (88/110 samples typed) and the
pfdhfr / pfdhps quadruple mutation (83/111 samples) ob-
served in this study is not very different from the results ob-
served after two years of implementation of SMC with SP
in infants in Senegal [7]. This is consistent with the results
obtained in Gabon, in Senegal and in Cameroon [14-16].ith parasitaemia pooled over the entire study
Crude prevalence ratio
SMC/ non SMC (95% CI)
Adjusted prevalence ratio*
SMC/ non SMC (95% CI)
p-value
1.10 (0.91, 1.32) 0.90 (0.79, 1.02) 0.087
1.15 (0.93, 1.42) 0.98 (0.80, 1.21) 0.867
1.18 (0.94, 1.49) 0.89 (0.75, 1.06) 0.182
1.32 (0.76, 2.31) 1.46 (0.70, 3.05) 0.311
1.93 (1.1, 3.38) 1.86 (1.04, 3.34) 0.037
0.96 (0.74, 1.26) 1.09 (0.82, 1.47) 0.550
1.39 (0.58, 3.37) 1.90 (0.71, 5.09) 0.205
1.50 (0.61, 3.72) 2.04 (0.73, 5.67) 0.173
sted for year of the study as described in the statistical methods.
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ples. Intergenic association of pfdhfr and pfdhps mutant
codons was found in other studies where SP resistance
was found to be associated with double up to quintuple
mutations in both genes [17,18].
The prevalence of pfcrt CVIET among children positive
at the end of the transmission season (10/38 in 2008, 16/
41 in 2009 and 10/27 in 2010) is low compared to previ-
ous estimates; the prevalence of pfcrt mutation between
2004 and 2006 was about 60% in Senegal and Kenya
[19,20]. This may be due to the fact that in Senegal, CQ
has been abandoned as first-line drug treatment against
malaria since 2002, first replaced with SP + AQ and from
2006 onwards with ACT. A substantial decrease in the
prevalence of mutations at the level of the pfcrt gene sev-
eral years after discontinuation of CQ as the first-line drug
was observed in Malawi by Kublin et al. [21] and Mita
et al. [22]. Over three years of SMC, the results showed
that the prevalence of pfcrt and pfmdr1 mutation was
more frequent in SMC areas but the only significant dif-
ference was for pfmdr1-86Y. The association mutations
pfcrt, pfmdr1, pfdhfr and pfdhps were demonstrated by au-
thors in West Africa and in Angola [23-25]. Almost all
isolates carrying the mutant genotype for pfdhfr or pfdhps
(conferring resistance to SP), carry at least one of the mu-
tations associated with AQ (pfcrt and or pfmdr1).
However, despite the high rates of mutations observed at
these genes, SP and/or AQ remain effective for the treat-
ment and prevention of malaria in West Africa [15,26-28].
The value of specific combinations of these molecular
markers for the predicting efficacy of SMC needs to be
established in settings with different levels of malaria trans-
mission and acquired immunity [29]. However, defining a
resistance threshold for acceptable efficacy may be prob-
lematic given that each SMC study will contribute only a
single data point to examine this relationship, as was the
case for studies of IPTi [30]. A limitation of this study is
that prevalence of resistant markers was measured only in
the target age group for SMC, and may not indicate
changes in prevalence of the different resistance genotypes
in the whole population.
The prevalence of different resistance genotypes at the
end of the transmission season may simply represent differ-
ential survival of resistant parasites, which is necessary but
not sufficient for SMC to lead to increased transmission of
drug resistant genotypes. Also relevant will be the relative
importance of children under five as a source of onward
transmission in relation to adults and older children. Adults
and older children will not receive SP+AQ for SMC and
should not receive SP or AQ for treatment of symptomatic
malaria where SMC is deployed. Consequently, because
prevalence among children treated with SMC is much
lower than among children who do not receive SMC, the
fraction of the total population with SP and AQ resistantparasites will be lower than if SMC is not used. Monitoring
among older children or adults was not undertaken in this
study, but should be used as a means to monitor
population-level changes in the prevalence of drug resist-
ance markers in the future. Molecular analysis using DNA
extracted from rapid diagnostic tests [31,32] would be one
practical approach to measure these changes.
Conclusion
The dhfr-dhps quintuple mutation was not observed in ei-
ther SMC or control health posts after three years of SMC
implementation in the study area. Analysis of individual
mutations showed that pfmdr1-86Y was more common
among children positive for parasites at the end of the
transmission season in SMC areas. However, the absolute
prevalence of resistance markers was lower in SMC areas,
reflecting the reduction in prevalence due to the interven-
tion, and this is not expected to compromise the efficacy
of regimens used for case management. Evaluation of the
prevalence of markers of drug resistance should be part of
routine monitoring and evaluation in areas where SMC is
deployed.
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